首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

2126721

肌萎縮側索硬化症 (ALS) 治療市場：按藥物類型、分銷管道和地區分類

Amyotrophic Lateral Sclerosis Treatment Market, By Drug Type, By Distribution Channel, By Geography

出版日期: 2026年08月10日 | 出版商:

Coherent Market Insights | 英文 256 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

肌萎縮側索硬化症 (ALS) 治療市場預計到 2026 年將達到 7.894 億美元，預計到 2033 年將達到 10.986 億美元。預計從 2026 年到 2033 年，該市場將以 6.1% 的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	7.894億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	6.10%	2033年市場規模預測：	10.986億美元

肌萎縮側索硬化症 (ALS) 治療市場涵蓋了有助於控制症狀、延緩疾病進展並改善患者生活品質的各種療法。 ALS 是一種進行性性神經退化性疾病，會影響運動神經元，導致肌肉無力、運動障礙和呼吸困難。人們對該疾病的認知不斷提高、神經學研究的進展以及對創新藥物研發投入的增加，正在推動市場成長。標靶治療的開發和診斷技術的改進，為有效管理 ALS 創造了新的機會。

製藥和生物技術公司正透過基因療法、幹細胞療法和精準醫療等方法推動肌萎縮側索硬化症（ALS）的治療研究。這些公司正在進行臨床試驗，以開發更安全、更有效的疾病修正治療。醫療保健支出不斷成長、監管政策支持力度加大以及對個人化醫療的需求日益成長，都促進了市場擴張。然而，治療選擇有限、治療費用高昂以及臨床開發的複雜性仍然是限制市場成長的挑戰。

市場動態

由於肌萎縮側索硬化症 (ALS) 的盛行率不斷上升、人們對神經退化性疾病的認知不斷提高，以及對有效疾病修正治療的需求日益成長，ALS 治療市場正在蓬勃發展。研究人員正致力於運用分子生物學、遺傳學研究和精準醫學方法開發創新療法。神經系統研究和開發資金的增加、診斷技術的進步以及有利的法規結構，都進一步推動了市場成長。新療法的出現為患者和醫療專業人員創造了新的機會。

製藥和生物技術公司正透過基因療法、幹細胞研究和標靶藥物研發項目，開發先進的ALS治療方法。這些公司正在擴大臨床試驗規模，並與研究機構合作，以加速治療創新。個人化醫療的引入使研發人員能夠為每位患者制定最佳化的治療方案。醫療保健投入的增加以及獲得專業神經科護理服務的途徑改善，也促進了ALS治療市場的成長。

由於治療選擇有限、疾病生物學機制複雜以及研發和治療高成本等因素，ALS治療市場仍面臨許多挑戰。企業需要應對臨床試驗的複雜性、監管障礙以及長期治療效果的不確定性。新興地區對該疾病的認知度低以及醫療資源匱乏進一步阻礙了市場成長。為了克服這些挑戰，業內相關人員正致力於降低治療成本、加強研發能力並開發更有效的治療方法。

本次調查的主要特點

該研究重點介紹了各個細分市場的潛在商機，並為參與肌萎縮側索硬化症 (ALS) 治療市場的相關人員提供了一個有吸引力的投資提案矩陣。
本研究深入分析了市場促進因素、限制因素、機會、新療法、基因療法和精準醫療的進展、臨床試驗趨勢、監管環境、區域展望以及主要市場參與企業所採用的競爭策略。
本研究基於公司簡介、產品系列、最新進展、臨床研發進展、研究舉措、監管批准和策略合作，分析了肌萎縮側索硬化症 (ALS) 治療市場的主要參與者。
本報告中的見解將使製藥公司、醫療保健提供者、投資者、研究人員和經營團隊能夠就 ALS 治療的開發、臨床研究投資、商業化策略、市場擴張、策略聯盟和創新做出明智的決策。
肌萎縮側索硬化症 (ALS) 治療市場報告的目標受眾廣泛，包括投資者、製藥製造商、生物技術公司、醫療機構、研究機構、神經科醫生、臨床相關人員、監管機構和金融分析師。
相關人員可以透過《肌萎縮側索硬化症 (ALS) 治療市場》報告中提出的分析框架、競爭基準、臨床管線評估、監管分析、技術評估和市場機會矩陣做出明智的策略決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第7章競爭情勢

熱圖分析
市佔率分析
公司簡介
- Mitsubishi Tanabe Pharma
- Takeda Pharmaceutical Company Limited
- Sanofi SA
- Mylan Pharmaceuticals Inc.
分析師意見

第8章

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI1206

Amyotrophic Lateral Sclerosis Treatment Market is estimated to be valued at USD 789.4 Mn in 2026 and is expected to reach USD 1,098.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 6.1% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 789.4 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	6.10%	2033 Value Projection:	USD 1,098.6 Mn

The Amyotrophic Lateral Sclerosis (ALS) Treatment Market includes therapies that help manage symptoms, slow disease progression, and enhance the quality of life of patients with this progressive neurodegenerative disorder. ALS affects motor neurons, causing muscle weakness, impaired movement, and respiratory difficulties. Rising disease awareness, advancements in neurological research, and increased investments in innovative drug development are driving market growth. The development of targeted therapies and improved diagnostic techniques is creating new opportunities for effective ALS management.

Pharmaceutical and biotechnology companies are advancing ALS treatment research through gene therapy, stem cell therapy, and precision medicine approaches. These companies are conducting clinical trials to develop safer and more effective disease-modifying therapies. Increasing healthcare spending, favorable regulatory support, and growing demand for personalized treatments are contributing to market expansion. However, limited therapeutic options, high treatment costs, and complexities in clinical development continue to challenge market growth.

Market Dynamics

The Amyotrophic Lateral Sclerosis (ALS) Treatment Market is growing as ALS prevalence increases, awareness of neurodegenerative diseases expands, and demand rises for effective disease-modifying therapies. Researchers are advancing molecular biology, genetic studies, and precision medicine approaches to develop innovative treatments. Increased funding for neurological research, improved diagnostic technologies, and supportive regulatory frameworks are further strengthening market growth. The launch of novel therapies is creating new opportunities for patients and healthcare professionals.

Pharmaceutical and biotechnology companies are developing advanced ALS treatments through gene therapy, stem cell research, and targeted drug discovery programs. These companies are expanding clinical trials and collaborating with research organizations to accelerate therapeutic innovation. The adoption of personalized medicine enables developers to create patient-specific treatment strategies. Rising healthcare investments and improved access to specialized neurological care are also contributing to the growth of the ALS treatment market.

The ALS Treatment Market continues to face challenges due to limited therapeutic options, complex disease biology, and high costs associated with research, development, and treatment. Companies encounter clinical trial complexities, regulatory barriers, and uncertainties regarding long-term treatment effectiveness. Limited disease awareness and inadequate healthcare access in emerging regions further impact market expansion. Industry participants are working to improve affordability, enhance research capabilities, and develop more effective therapies to overcome these challenges.

Key Features of the Study

It highlights potential revenue opportunities across various market segments and provides attractive investment proposition matrices for stakeholders involved in the Amyotrophic Lateral Sclerosis (ALS) Treatment Market.
This study offers key insights into market drivers, restraints, opportunities, emerging therapies, advancements in gene therapy and precision medicine, clinical trial developments, regulatory landscape, regional outlook, and competitive strategies adopted by leading market participants.
It profiles key players in the Amyotrophic Lateral Sclerosis (ALS) Treatment Market based on company overview, product portfolio, recent developments, clinical pipeline advancements, research initiatives, regulatory approvals, and strategic collaborations.
Key companies covered as part of this study include Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company Ltd., Sanofi S.A., and Mylan Pharmaceuticals Inc.
Insights from this report enable pharmaceutical companies, healthcare providers, investors, researchers, and management teams to make informed decisions regarding therapeutic development, clinical research investments, commercialization strategies, market expansion, strategic partnerships, and innovation in ALS treatment.
The Amyotrophic Lateral Sclerosis (ALS) Treatment Market report serves a wide range of stakeholders, including investors, pharmaceutical manufacturers, biotechnology companies, healthcare organizations, research institutions, neurologists, clinical researchers, regulatory bodies, and financial analysts.
Stakeholders can make well-informed strategic decisions through the analytical frameworks, competitive benchmarking, clinical pipeline assessment, regulatory analysis, technology evaluation, and market opportunity matrices presented in the Amyotrophic Lateral Sclerosis (ALS) Treatment Market report.

Market Segmentation

By Drug Type (Revenue, USD Mn, 2021-2033)
Riluzole
Edaravone (Radicava)
By Distribution Channel (Revenue, USD Mn, 2021-2033)
Hospital Pharmacies
Retail & Online Pharmacies
By Region (Revenue, USD Mn, 2021-2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Key Players
Mitsubishi Tanabe Pharma
Takeda Pharmaceutical Company Ltd.
Sanofi S.A.
Mylan Pharmaceuticals Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Product Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Global Amyotrophic Lateral Sclerosis Treatment Market, By Drug Type, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Riluzole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Edaravone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

5. Global Amyotrophic Lateral Sclerosis Treatment Market, By Distribution Channel, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Retail & Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

6. Global Amyotrophic Lateral Sclerosis Treatment Market, By Region, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- Mitsubishi Tanabe Pharma
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Takeda Pharmaceutical Company Limited
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Sanofi S.A.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Mylan Pharmaceuticals Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
Analyst Views